Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 18,052 Shares

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey purchased 18,052 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were purchased at an average price of $19.60 per share, with a total value of $353,819.20. Following the completion of the acquisition, the director directly owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. This trade represents a 1.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Tim Kutzkey also recently made the following trade(s):

• On Friday, January 16th, Tim Kutzkey acquired 2,562 shares of Surrozen stock. The shares were acquired at an average cost of $20.00 per share, with a total value of $51,240.00.
• On Thursday, January 15th, Tim Kutzkey bought 11,893 shares of Surrozen stock. The shares were acquired at an average price of $19.89 per share, with a total value of $236,551.77.
• On Wednesday, January 14th, Tim Kutzkey bought 5,523 shares of Surrozen stock. The stock was acquired at an average cost of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 13th, Tim Kutzkey purchased 12,470 shares of Surrozen stock. The shares were acquired at an average price of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey acquired 15,100 shares of Surrozen stock. The stock was acquired at an average cost of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The stock was bought at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey bought 5,266 shares of Surrozen stock. The shares were bought at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The shares were bought at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Price Performance

Shares of Surrozen stock opened at $17.98 on Wednesday. The company has a market cap of $154.09 million, a PE ratio of -0.80 and a beta of 0.58. The firm has a fifty day moving average price of $18.98 and a two-hundred day moving average price of $14.13. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $24.94.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The company had revenue of $0.98 million for the quarter. Analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SRZN. Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $32.00.

Trending Headlines about Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed three open‑market buys on Jan 15, Jan 16 and Jan 20 totaling 32,507 shares (~$641k at the reported prices). After the trades he directly owns ~1.02M shares (≈$19.9M value), a roughly 1–1.8% increase in his position; insider buys can be read as a vote of confidence by management. SEC filing — Kutzkey purchases
• Positive Sentiment: Major shareholder Group Gp Lp Column III mirrored the same purchases (Jan 15, 16, 20) for the same share counts and prices, increasing its stake to ~1.02M shares; large‑holder buying reinforces the insider signal and suggests continued institutional support. SEC filing — Group purchases
• Neutral Sentiment: The transactions were disclosed via routine SEC beneficial‑ownership filings; they do not change reported board composition or indicate corporate action (e.g., buyback or financing) beyond increased insider/holder positions. SEC website
• Negative Sentiment: Fundamentals remain a headwind: Surrozen reported a large Q3 earnings miss (EPS -$3.61 vs. -$1.17 expected) and minimal revenue, leaving the company with deep losses — this weak financial profile is the likely driver of downward pressure on the stock despite insider buying. MarketBeat — SRZN profile

Institutional Trading of Surrozen

A number of large investors have recently bought and sold shares of SRZN. Citadel Advisors LLC lifted its position in shares of Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares in the last quarter. Acuta Capital Partners LLC raised its position in Surrozen by 5.0% in the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after purchasing an additional 8,415 shares during the last quarter. Stonepine Capital Management LLC raised its position in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Surrozen by 21.7% during the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after buying an additional 47,468 shares in the last quarter. 66.57% of the stock is currently owned by institutional investors.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.